The House has passed the Medical Marijuana Research Act as with SAFE the already answered question is…. will it get through the Senate? Unlikely with McConnell at the helm which is why the upcoming Georgia vote is so important for the sector.
CLICK ON IMAGE TO READ FULL TEXT OF THE BILL
More primary info at
As… MJ Biz reports
Passage of the bill – while largely symbolic – marks the second significant marijuana victory on Capitol Hill in the past week.
“Cannabis laws in this country are broken, especially those that deal with research,” Rep. Earl Blumenauer, an Oregon Democrat and prime sponsor of the bill, said during a brief floor debate.
A number of Republican lawmakers also spoke in support of the bill.
Greg Walden, an Oregon Republican, stressed that there currently is an “information vacuum” on the health aspects of medical marijuana and that the current lack of research is a “significant factor” why rescheduling petitions to the DEA are denied.
He said expanded research will help give consumers the information they need.
Walden did criticize the House for passing the legalization bill last week without that science in hand and said any discussion of marijuana rescheduling must be preceded by more knowledge of the risks of cannabis use.
Andrew Harris, a Maryland Republican and physician who also supported the research bill, said: “We don’t tolerate not having the science for other medications.”
Read their full report at
Other Useful ResourcesHHRG-116-IF14-20200115-SD009
Article: The State of Cannabis Research Legislation in 2020
As growing numbers of Americans use federally unregulated cannabis products and develop complications — such as psychosis, cannabis use disorder, and electronic-cigarette, or vaping, product use–associated lung injury (EVALI) — the need to facilitate research on the products that our patients purchase from dispensaries is becoming increasingly pressing. Patients in our clinics routinely report using vape pens, dabs, waxes, edibles, and oils purporting to contain various concentrations of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC). Physicians register patients to obtain medicinal cannabis, counsel them on safe use of cannabis products, and monitor them for side effects of such products, yet they don’t have access to reliable evidence on the effects of the products that patients are using.
Full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302267/